Additional Details

  • Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

    University of Michigan Health System
    Michigan Center MI. 48109
    View Details

  • Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

    University of Pittsburgh Medical Center
    Pittsburgh PA. 15213
    View Details

  • Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

    Tufts Medical Center
    Boston MA. 02111
    View Details

  • Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

    Duke University Medical Center
    Durham NC. 27705
    View Details

  • Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

    Dignity Health Norton Thoracic Institute
    Phoenix AZ. 85013
    View Details

  • Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

    Lowcountry Lung and Critical Care
    Charleston SC. 29406
    View Details

  • Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

    Pulmonary Associates, PA
    Mesa AZ. 85206-1346
    View Details

  • Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

    The Lung Research Center, LLC
    Chesterfield MO. 63017
    View Details

  • Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

    University of Kansas Medical Center Research Institute, Inc
    Kansas City KS. 66160
    View Details

  • FAPI PET for Lung Fibrosis

    UCLA Health Westwood Medical Plaza
    Westwood CA. 90095
    View Details

  • FAPI PET for Lung Fibrosis

    UCLA / Jonsson Comprehensive Cancer Center
    Los Angeles CA. 90095
    View Details

  • Effect of CPAP on Abnormal Gastroesophageal Reflux and Lung Inflammation in IPF

    University of Arizona
    Tucson AZ. 85724
    View Details

  • Transplantation Using Hepatitis C Positive Donors, A Safety Trial

    University Health Network Toronto General Hospital
    Toronto ON. M5G 2N2
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    UCLA Health Westwood Medical Plaza
    Westwood CA. 90095
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    National Jewish Health Medical Center ( Site 4015)
    Denver CO. 80206
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    University of Michigan Hospital ( Site 4001)
    Ann Arbor MI. 48109
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    Rutgers Robert Wood Johnson Medical School ( Site 4013)
    New Brunswick NJ. 08901
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    UT Physicians Rheumatology ( Site 4007)
    Houston TX. 77030
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    St. Joseph's Health Care London ( Site 4701)
    London ON. N6A 4V2
    View Details

  • Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

    MedStar Georgetown University Hospital ( Site 4005)
    Washington DC. 20007
    View Details